Tempest Therapeutics (TPST) announced it received a delisting notice from The Nasdaq Stock Market on November 17, 2026. The notice was issued because the company failed to regain compliance with the minimum stockholders' equity requirement of $2.5 million by the extended deadline of November 16, 2026.

Key Details

  • Non-Compliance: The company failed to meet Nasdaq Listing Rule 5550(b)(1) by not completing a necessary capital-raising transaction to meet the $2.5 million minimum stockholders' equity threshold.
  • Company Action: Tempest plans to appeal the determination by requesting an oral hearing before the Nasdaq Hearings Panel. This action will temporarily stay the delisting.
  • Trading Status: The company's common stock will continue to trade on the Nasdaq Capital Market pending the outcome of the appeal hearing.